Workshop Day

24th February 2020

 Translation

Manufacturing

 

 

B 9am-11am

Manufacturing for an Allogeneic Future

Ali Mohamad, VP CMC, Immatics

 

12pm-2pm

Redefining Preconditioning Standards for Malignancies Beyond CD19

John Maher, Immunology Consultant, King’s College London / CSO, Leucid Bioy

 

 

 

G 3pm-5pm

CAR T Cells for Solid Tumours, To Do List (TEO):

Francesco Marincola, Chief Scientific Officer, Biotech Refuge
Zhifen Yang, Senior Scientist, Refuge Biotech

 

H 3pm-5pm

Driving Analytical Development to Reduce Time and Cost

Eric Alonzo, Senior Scientist, Cell Analytics, bluebird bio

 

Translation

Workshop D 12pm-2pm

Redefining Preconditioning Standards for Malignancies Beyond CD19
• Review potential solutions for preconditioning toxicity
• Strategies to reduce the dose of preconditioning to allow quick supply and safe treatment, securing the value in patient safety
• Case study: T4 immunotherapy of head and neck cancer (Phase I trial) – the case for lymphodepletion
• Preclinical evaluation of pan ErbB targeted T4 immunotherapy
• Dose escalation of intratumoural T4 immunotherapy in SCCHN
• Plans and experience to date with lymphodepletion prior to intratumoural T4 immunotherapy
John Maher, Immunology Consultant, King’s College London / CSO, Leucid Bioy

Workshop G 3pm-5pm

CAR T Cells for Solid Tumours, To Do List (TEO):
• Traffic (how to get to the tumours, relevant to silent, non chemoattractant or chemorepulsive tumours)
• Engage (how to penetrate and engage with tumour cells, relevant to immune excluded tumours)
• Overcome (how to overcome immune suppression/compensatory immune suppression, relevant to inflamed tumours)
Francesco Marincola, Chief Scientific Officer, Biotech Refuge

Manufacturing

Workshop B 9am-11am

Manufacturing for an Allogeneic Future
• Overcome variation in starting materials with uniform cells sourced from healthy donors
• Control and predict safety and efficacy with standardisedcell banks
• Creating reproducible and consistent products, managing quality specifications
• Explore methods to carry out large scale expansion whilst preserving efficacy and potency
• Lessons learned to translate reproducible, safe and virus free constructs
Ali Mohamad, VP, CMC, Immatics
Therapeutics

Workshop H 3pm-5pm

Driving Analytical Development to Reduce Time and Cost
• Innovations in analytical testing with automation in batch records
• Discuss the need to speed up the process for QP to release product
• Overcome the burden of release through novel quality, safety and efficacy testing
Therese Choquette, Analytical Project Leader & Senior
Fellow, Novartis